30
Views
4
CrossRef citations to date
0
Altmetric
I. PROGRESS IN SECOND GENERATION OLIGOMER THERAPEUTICS

The Synthesis of the Sixteen Possible 2′-O-Methyl MMI Dimer Phosphoramidites: Building Blocks for the Synthesis of Novel Antisense Oligonucleotides

, , &
Pages 971-972 | Published online: 16 Aug 2006

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Didier Peoc'h, EricE. Swayze, Balkrishen Bhat, Stuart Dimock, Richard Griffey & YogeshS. Sanghvi. (1997) Synthesis and Evaluation Of 2″-Modified MMI Linked Dimers in Antisense Constructs. Nucleosides and Nucleotides 16:7-9, pages 959-962.
Read now
YogeshS. Sanghvi, EricE. Swayze, Didier Peoc'h, Balkrishen Bhat & Stuart Dimock. (1997) Concept, Discovery and Development of MMI Linkage: Story of a Novel Linkage: for Antisense Constructs. Nucleosides and Nucleotides 16:7-9, pages 907-916.
Read now

Articles from other publishers (2)

Guillermo VasquezMichael T. MigawaW. Brad WanAudrey LowMichael TanowitzEric E. SwayzePunit P. Seth. (2022) Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides. Nucleic Acid Therapeutics 32:1, pages 40-50.
Crossref
RICHARD I. HOGREFE. (1999) An Antisense Oligonucleotide Primer. Antisense and Nucleic Acid Drug Development 9:4, pages 351-357.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.